Purpose of this Study
We are doing this study to find the safest and most effective dose of an experimental drug called ZL-1310 (the study drug). We want to know if this drug can be beneficial for people with small cell lung cancer (SCLC) that progressed after at least one round of chemotherapy.
Who Can Participate?
Eligibility
Adults ages 18+ who:<ul>
<li>Are diagnosed with SCLC that did not respond to treatment</li>
<li>Have received at least one line of chemotherapy</li></ul>
For more information about who can join this study, please contact the study team at <a href= "mailto: annemarie.peters@duke.edu">annemarie.peters@duke.edu.</a>
<li>Are diagnosed with SCLC that did not respond to treatment</li>
<li>Have received at least one line of chemotherapy</li></ul>
For more information about who can join this study, please contact the study team at <a href= "mailto: annemarie.peters@duke.edu">annemarie.peters@duke.edu.</a>
What is Involved?
If you choose to join this study, you will get the study drug once every 3 weeks. The drug is given as an intravenous (IV) infusion. The study drug will be given at various doses during the study. Your dose of study drug will depend on when you join the study.
You will continue to receive the study drug for as long as the study doctor and you feel that you are getting a benefit.
You will continue to receive the study drug for as long as the study doctor and you feel that you are getting a benefit.
Study Details
Full Title
An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer (Site #2001) - Protocol number: ZL-1310-001
Principal Investigator
Jeffrey
Clarke
Protocol Number
PRO00114821
NCT ID
NCT06179069
Phase
I
Enrollment Status
Open to Enrollment